CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Feb 6, 2023 → Jul 31, 2023
NCT ID
NCT05725434About CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) is a phase 3 stage product being developed by Celltrion for Rheumatoid Arthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05725434. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05725434 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Rheumatoid Arthritis